pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace. About the Author.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

The Marketing Advantage

MAY 8, 2023

May 9, 2023 Since the Orphan Drug Act was passed in 1983, the number of products being researched and approved for rare and orphan diseases has increased dramatically, offering hope and life-saving treatments for the millions of patients affected by these often under-served conditions. A member of our team will be in touch shortly.

Sales 52

Sales Physicians Consulting Education 52

pharmaphorum

JULY 27, 2022

Demerging Haleon has allowed GSK to focus on higher-margin prescription medicines and vaccines, as well as provide cash for investment in its biopharma pipeline. GSK’s HIV business, run through joint venture company ViiV Healthcare, also had a good quarter with sales up 14% to £1.4 Total revenues came in at £6.9 billion ($8.3

Sales 52

Sales Biopharma Prescription Medicine 52

MedCity News

MARCH 18, 2024

As GenAI and other technologies advance the speed of development and the precision of drugs, pharma commercial teams need to make sure they are harvesting the right data with the right AI tools in order to ultimately reach the right patients.

Pharma 107

Pharma Marketing Sales Patients 107

pharmaphorum

SEPTEMBER 21, 2022

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. billion or more. billion or more.

Sales 108

Sales Biopharma Medicine Patients 108

Pharmaceutical Technology

MAY 9, 2023

The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs.

Biopharma 104

Biopharma Sales Leads Patients 104

Pharmaceutical Technology

APRIL 20, 2023

CBC CEO Fu Wei stated: “Hasten is a well-established Chinese biopharma company with tremendous growth potential. The firm reported 47% growth in sales from Q2 to Q4 in 2022, which is testament to CBC’s unique and effective investor-operator strategy. “We

Biopharma 98

Biopharma Healthcare Healthcare Sales 98

The Marketing Advantage

FEBRUARY 26, 2024

Not only does the rare disease space differ considerably from therapeutic areas with much larger patient populations, but the space differs drastically from one rare disease to another. Request a Free Consultation Request a Free Consultation Name * First Name Last Name Company * Title Email * Phone (###) ### #### Message Thank you!

Sales 52

Sales Consulting Prospecting Biopharma 52

Pharmaceutical Technology

NOVEMBER 24, 2022

Xeris Biopharma and Horizon Therapeutics have sig n ed a research partnership and option agreement for developing a ready-to-use, highly-concentrated, subcutaneous injection of teprotumumab. Xeris is entitled to receive royalty payments based on product sales in the future, on exercising the commercial licence option.

Food and Drug Administration 52

Food and Drug Administration Biopharma Food Sales 52

European Pharmaceutical Review

APRIL 18, 2023

GSK has agreed to acquire late-stage biopharma BELLUS Health, for a total of £1.6 Camlipixant, a novel P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential,” Miels added. According to GSK, the P2X3 antagonist has the potential to deliver significant sales through 2031 and beyond.

Biopharma 81

Biopharma Sales Patients Medical 81

pharmaphorum

OCTOBER 25, 2022

AstraZeneca’s IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker’s efforts to expand its label keep running into difficulties. billion in sales last year. billion for AZ last year – is looking increasingly difficult.

FDA 104

FDA Sales Biopharma Engineering 104

pharmaphorum

NOVEMBER 24, 2022

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). Response rates above 50% in PD-1 high/intermediate patients with no liver tox surprises could set up for a potential acquisition.”

Pharma 103

Pharma Biopharma FDA Competition 103

pharmaphorum

NOVEMBER 18, 2022

Dr John Lin, senior vice president of immune-oncology and head of bispecifics at Regeneron , said: “The collaboration will enable Regeneron and CytomX to combine our collective oncology expertise with two premier platforms […] to develop novel immunotherapies and research their potential to transform patient lives.”.

Biopharma 95

Biopharma Physicians Sales Patients 95

pharmaphorum

JANUARY 3, 2023

The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months. in the evenamide group.

Side effects 104

Side effects Biopharma Patients Competition 104

pharmaphorum

JANUARY 9, 2023

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. Chief executive officer of Chiesi Group , Marco Vecchia, said: “This addition of the Amryt portfolio, as well as their expertise, will help us on our journey to bring medicines to patients, no matter how rare their condition may be.”. in an all-cash transaction at $14.50

Pharma 91

Pharma Biopharma Management Medicine 91

Pharmaceutical Technology

DECEMBER 20, 2022

The deal is pursuant to the existing strategic collaboration of the companies for expanding patient access to new therapeutics in Greater China. It is currently being assessed to treat RSV infection in paediatric and adult patients.

Biopharma 64

Biopharma Pharmaceutical products Patients Pharmaceutical 64

Pharmaceutical Technology

JUNE 29, 2022

Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. The quality grade is even more important in many novel therapeutic modalities because the specialty enzymes often form an integral part of the product and are closer to the patient.

Specialization 118

Specialization Biopharma B2B Sales Manufacturing 118

PM360

OCTOBER 3, 2023

Director US Marketing and Patient Engagement, argenx US, Inc. Men’s Health: Nuvan Augustin Dassanaike, Senior Vice President Digital and Marketing Strategy & Operations, Accord BioPharma Nephrology/Urology: W. and Publicis NY) BRAND CHAMPION AWARD WINNERS Autoimmune/Rheumatology: Katrina Sergeev Gary, Sr. Cardiology: Bradley A.

Education 122

Education Marketing Media Management 122

pharmaphorum

OCTOBER 27, 2022

The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned. “We look forward to working closely with US regulators to advance vamorolone towards approval,” he added.

FDA 92

FDA Side effects Biopharma Marketing 92

pharmaphorum

DECEMBER 6, 2022

Moderna is also suing Pfizer and BioNTech in Germany, and if it wins in both suits could claim a royalty on COVID-19 vaccine sales, although these have been falling and are expected to fall further if the pandemic continues to abate. The post Pfizer/BioNTech strike back in Moderna COVID vaccine lawsuit appeared first on.

Biopharma 87

Biopharma Sales Marketing Patients 87

MedCity News

FEBRUARY 16, 2023

While Talaris Therapeutics is ending two clinical tests of its cell therapy in kidney transplant patients, a third study in the autoimmune condition scleroderma is continuing. Meanwhile, the biotech’s restructuring plan is pursuing “strategic alternatives” that could include a merger or sale.

Sales 98

Sales Patients Biopharma Pharma 98

European Pharmaceutical Review

JANUARY 24, 2023

Takeda has entered into an exclusive licensing agreement with biopharma HUTCHMED, to develop and commercialise t yrosine kinase inhibitor fruquintinib, refractory metastatic colorectal cancer (CRC) for outside of mainland China, Hong Kong and Macau. This is in addition to royalties on net sales. The agreement is valued up to $1.13

Food and Drug Administration 52

Food and Drug Administration Biopharma Medical Sales 52

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). Contingent to the cost and profit-sharing option of Sutro for the US region, the company will receive tiered royalties on global commercial product sales.

Biopharma 105

Biopharma Engineering Marketing Pharma 105

PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. ABIGAIL MALLON Chief Patient Experience Officer, VMS BioMarketing Physician burnout is on the rise. PM360’s Focus On section examines examines a specific area of the life sciences industry.

Education 59

Education Physicians Healthcare Healthcare 59

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. How can we maximise marketing, sales, medical, access, and other teams’ efforts while making their jobs easier? Harnessing data to understand the patient journey.

Competition 95

Competition Marketing Pharma Biopharma 95

Impetus Digital

JANUARY 11, 2023

He will also explore how to create equitable access to advanced AI-based diagnostics and treatment pathways, how biopharma companies can leverage federated learning to overcome the challenges of accessing real-world data, and more. Register now! Register for this free webinar. About Impetus Digital. Book a Consultative Demo.

Professional Services 52

Professional Services Healthcare Healthcare Biopharma 52

pharmaphorum

JANUARY 10, 2023

With one in five agreeing that it is important to shift from a ‘sales’ to a ‘customer success’ focus, what comes across in the report, however, is pharma’s commitment to putting HCPs and patients at the forefront of considerations going forward. What is your definition of success? is to acquire the 2015-established Amryt Pharma Plc.

Pharma 52

Pharma Specialization Sales Biopharma 52

PM360

NOVEMBER 27, 2023

I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. We’re creating a compliant engine that will help reach healthcare professionals (HCPs) and patients faster with content that resonates.

Marketing 105

Marketing Customer Relationship Management Relationship management Education 105

pharmaphorum

OCTOBER 24, 2022

Sumitomo and its subsidiary Sumitovant Biopharma initially offered $22.75 Sales of the two products were $4 million and $36 million respectively in Myovant’s fiscal first quarter ended 30 June 2022. Pfizer agreed a $4.2

Biopharma 69

Biopharma Pharma Marketing Prescription 69

pharmaphorum

NOVEMBER 15, 2022

Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

Biopharma 52

Biopharma FDA Pharma Sales 52

Clarivate

MAY 8, 2023

That was the overarching sentiment from the experienced group of biopharma leaders that formed the panel discussion chaired by Mike Ward, Clarivate Global Head of Life Sciences and Healthcare Thought Leadership, at this year’s AngloNordic Life Science conference. You have to be patiently impatient,” he said. Timing is everything.

Biopharma 52

Biopharma Sales Networking Pharma 52

PM360

OCTOBER 5, 2023

Now, Real Chemistry is at the forefront of applying analytics, data, and artificial intelligence to the biopharma and healthcare industry and, in 2022, the company achieved its 21st consecutive year of double-digit growth. Director US Marketing and Patient Engagement, argenx US, Inc. Cardiology: Bradley A.

Education 52

Education Marketing Media Biopharma 52

PM360

JULY 21, 2022

Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. 3 Sales reps’ meetings with physicians also shifted from 64% in-person prior to the COVID-19 pandemic to 65% virtual during the pandemic. THE CHALLENGE. References: 1.

Physicians 52

Physicians Media Pharma sales reps Electronics 52

pharmaphorum

DECEMBER 28, 2022

The US regulator has placed oral BTK inhibitor orelabrutinib on partial clinical hold, meaning new patients cannot be enrolled into clinical trials and patients treated with the drug for 70 days or less must discontinue treatment. billion buyout of Principia Biopharma.

FDA 72

FDA Side effects Biopharma Prospecting 72

Prognos Health

FEBRUARY 1, 2022

sales, and more than half failed to reach $250 million Poor launch results were seen across all therapeutic areas, with cardiovascular and infectious disease drugs among the poorest performing. The consultant’s data shows that average peak sales for new products is 50% higher in Big Pharma than it is among smaller players.

Consulting 52

Consulting Physicians Pharma Biopharma 52

Clarivate

JANUARY 8, 2024

These new treatments hold tremendous promise to advance patient care and fuel the next generation of medical breakthroughs. Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion for NSCLC and breast cancer combined.

Marketing 59

Marketing Patients Healthcare Healthcare 59

PM360

AUGUST 24, 2023

Each of their trailblazing efforts result in much more than personal or organization success, it results in better quality of life for patients, better care options for healthcare providers, and happier and healthier people around the world.” Director US Marketing and Patient Engagement, argenx US, Inc. Braun Medical, Inc.

Marketing 52

Marketing Education Media Healthcare 52